Decoding the microbiome
to redefine therapeutics
Decoding the microbiome
to redefine therapeutics
Decoding the microbiome
to redefine therapeutics
An incredible opportunity for therapeutics
An incredible opportunity for therapeutics
We design and develop complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and chronic diseases.
Our Vision
Our goal is to access the gut microbiome’s full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease
Bringing together proprietary precision analytics and patient insights, we are building a pipeline of rationally selected microbial communities to achieve indication-specific treatment and address patient
Our Vision
Our goal is to access the gut microbiome’s full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease
Bringing together proprietary precision analytics and patient insights, we are building a pipeline of rationally selected microbial communities to achieve indication-specific treatment and address patient heterogeneity.
Our Vision
Our goal is to access the gut microbiome’s full immunological and metabolic potential to restore healthy microbial ecosystems and thereby overcome disease
Bringing together proprietary precision analytics and patient insights, we are building a pipeline of rationally selected microbial communities to achieve indication-specific treatment and address patient heterogeneity.
Our People
A top-tier team of groundbreaking scientists, researchers, and AI specialists across the full spectrum of discovery, development, and delivery.
Leadership Team
Kristin Torre Vinuesa
CFO
Managing Director
Kristin Torre Vinuesa
CFO
Managing Director
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Christopher Weidenmaier
CSO
Dr. Christopher Weidenmaier
CSO
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Board Member
Job title
Board Member
Job title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Board Member 2
Job title
Board Member 2
Job title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Board Member 3
Job title
Board Member 3
Job title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Our People
A top-tier team of groundbreaking scientists, researchers, and AI specialists across the full spectrum of discovery, development, and delivery.
Leadership Team
Kristin Torre Vinuesa
CFO
Managing Director
Kristin Torre Vinuesa
CFO
Managing Director
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Christopher Weidenmaier
CSO
Dr. Christopher Weidenmaier
CSO
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Our People
A top-tier team of groundbreaking scientists, researchers, and AI specialists across the full spectrum of discovery, development, and delivery.
Leadership Team
Kristin Torre Vinuesa
CFO
Managing Director
Kristin Torre Vinuesa
CFO
Managing Director
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Dr. Johannes Wöhrstein
CEO
Managing Director
Co-Founder
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Dr. Christopher Weidenmaier
CSO
Dr. Christopher Weidenmaier
CSO
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean maximus eu velit sit amet semper. Sed in lacus accumsan, laoreet nibh quis, porttitor ipsum. Curabitur malesuada lorem risus.
Our Technology
Our Technology
Our Technology
Next-Generation Microbiome Products
We are recapitulating the clinical efficacy of fecal transplants by designing complex consortia with superior safety and disease-specific activity. Our proprietary technology gives a competitive advantage on critical workstreams for microbiome therapeutics development
1.
Large Consortia Design
The mbiomics data science platform allows the design of effective large consortia products by predicting indication-specific MoAs and taxa
Backbone strains
MoA-specific strains
Indication-specific strains
1.
Large Consortia Design
The mbiomics data science platform allows the design of effective large consortia products by predicting indication-specific MoAs and taxa
Backbone strains
MoA-specific strains
Indication-specific strains
2.
Proprietary Strain Library
Our proprietary strain library enables us to translate an in silico consortia design to the laboratory
A. muciniphila
Strain Type
2.
Proprietary Strain Library
Our proprietary strain library enables us to translate an in silico consortia design to the laboratory
A. muciniphila
Strain Type
3.
Co-culturing Manufacturing
mbiomics has developed an in-house process allowing co-culturing of 100+ species
3.
Co-culturing Manufacturing
mbiomics has developed an in-house process allowing co-culturing of 100+ species
4.
Analytics
mbiomics proprietary technology can precisely track number and viability indicators of individual strains over time for optimal manufacturing
Tracking
4.
Analytics
mbiomics proprietary technology can precisely track number and viability indicators of individual strains over time for optimal manufacturing
Tracking
5.
Screening
An innovative screening platform for large consortia allows nomination of candidates for GMP production and accelerates pipeline development
Optimised Composition
In-vitro Screening
In-vivo Screening
mbiomics Live Biotherapeutic
5.
Screening
An innovative screening platform for large consortia allows nomination of candidates for GMP production and accelerates pipeline development
Optimised Composition
In-vitro Screening
In-vivo Screening
mbiomics Live Biotherapeutic
100+
Rationally selected strains
Consistent
Indication Specific
Scalable
Introducing the mbiomics
Live Biotherapeutic Product
Introducing the mbiomics
Live Biotherapeutic Product
Introducing the mbiomics
Live Biotherapeutic Product
mbiomics develops live biotherapeutic products (LBPs) to transform the treatment paradigm of severe and chronic disease
100+
100+
Rationally selected strains
Rationally selected strains
Consistent
Consistent
Indication Specific
Indication Specific
Scalable
Scalable
Therapeutic Pipeline
Therapeutic Pipeline
Programs
Discovery
Discovery
Discovery
Preclinical
Preclinical
Preclinical
Phase 1
Phase 1
Phase 1
Phase 2
Phase 2
Phase 2
MBX-116
Melanoma
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
MBX-116 is our lead checkpoint-inhibitor co-therapy designed to enhance immunotherapy response in advanced melanoma.
Targeted microbial modulation to boost checkpoint inhibitor response.
First-in-human evaluation with adaptive Phase 1/2 design and accelerated development.
Platform demonstrator with planned expansion into additional indications.
Non-small cell lung cancer/ Renal Cell Carcinoma
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
MBX-116
Melanoma
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
MBX-116 is our lead checkpoint-inhibitor co-therapy designed to enhance immunotherapy response in advanced melanoma.
Targeted microbial modulation to boost checkpoint inhibitor response.
First-in-human evaluation with adaptive Phase 1/2 design and accelerated development.
Platform demonstrator with planned expansion into additional indications.
Non-small cell lung cancer/ Renal Cell Carcinoma
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
Undisclosed
IBD
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
Undisclosed
IBD
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
Undisclosed
ASD
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.
Background
Undisclosed
ASD
Target
Development Candidate
Lorem ipsum.
Modality
Lorem ipsum.